1. Time for Cooperation in Health Economics among the Modelling Community

   • Renée J. G. Arnold
   • Sean Ekins

   Commentary 29 September 2012 Pages: 609 - 613

   

2. Financial Effects of Pharmaceutical Price Regulation on R&D Spending by EU versus US Firms

   • Joseph Golec
   • John A. Vernon

   Leading Article 29 September 2012 Pages: 615 - 628

   

3. Cost Effectiveness of Cytotoxic and Targeted Therapy for Metastatic Breast Cancer

   • Patricia R. Blank
   • Konstantin J. Dedes
   • Thomas D. Szucs

   Review Article 29 September 2012 Pages: 629 - 647

   

4. Impact of European Pharmaceutical Price Regulation on Generic Price Competition

   • Jaume Puig-Junoy

   Review Article 29 September 2012 Pages: 649 - 663

   

5. Assessing the Relationship between Computational Speed and Precision

   • Phil McEwan
   • Klas Bergenheim
   • Jason P. Gordon

   Original Research Article 29 September 2012 Pages: 665 - 674

   

6. Economic Burden of Epilepsy among the Privately Insured in the US

   • Jasmina I. Ivanova
   • Howard G. Birnbaum
   • Sue Caleo

   Original Research Article 29 September 2012 Pages: 675 - 685

   

7. Fondaparinux

   • Kate McKeage
   • Katherine A. Lyseng-Williamson

   Adis Pharmaeconomic Drug Evaluation 29 September 2012 Pages: 687 - 698